Northern Trust
BBIO icon

Northern Trust’s BridgeBio Pharma BBIO Stock Holding History

Northern Trust’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$104M Buy
1,403,642
+56,888
+4% +$4.12M 0.01% 719
2025
Q4 		$103M Sell
1,346,754
-55,655
-4% -$3.65M 0.01% 728
2025
Q3 		$72.8M Buy
1,402,409
+38,726
+3% +$1.89M 0.01% 896
2025
Q2 		$58.9M Buy
1,363,683
+76,836
+6% +$2.79M 0.01% 995
2025
Q1 		$44.5M Sell
1,286,847
-36,411
-3% -$1.23M 0.01% 1152
2024
Q4 		$36.3M Buy
1,323,258
+43,955
+3% +$1.14M 0.01% 1320
2024
Q3 		$32.6M Buy
1,279,303
+150,284
+13% +$3.95M 0.01% 1312
2024
Q2 		$28.6M Sell
1,129,019
-190
-0% -$5.2K ﹤0.01% 1339
2024
Q1 		$34.9M Sell
1,129,209
-25,763
-2% -$876K 0.01% 1236
2023
Q4 		$46.6M Buy
1,154,972
+1,057
+0.1% +$31.7K 0.01% 1057
2023
Q3 		$30.4M Buy
1,153,915
+24,643
+2% +$699K 0.01% 1268
2023
Q2 		$19.4M Buy
1,129,272
+171,915
+18% +$2.59M ﹤0.01% 1601
2023
Q1 		$15.9M Buy
957,357
+16,189
+2% +$189K ﹤0.01% 1706
2022
Q4 		$7.17M Buy
941,168
+5,130
+0.5% +$49.1K ﹤0.01% 2235
2022
Q3 		$9.3M Sell
936,038
-30,513
-3% -$317K ﹤0.01% 2026
2022
Q2 		$8.78M Sell
966,551
-30,739
-3% -$257K ﹤0.01% 2124
2022
Q1 		$10.1M Sell
997,290
-14,478
-1% -$149K ﹤0.01% 2141
2021
Q4 		$16.9M Sell
1,011,768
-103,631
-9% -$4.38M ﹤0.01% 1897
2021
Q3 		$52.3M Buy
1,115,399
+37,336
+3% +$2M 0.01% 1042
2021
Q2 		$65.7M Buy
1,078,063
+49,053
+5% +$2.8M 0.01% 923
2021
Q1 		$63.4M Buy
1,029,010
+196,174
+24% +$12.8M 0.01% 936
2020
Q4 		$59.2M Sell
832,836
-19,704
-2% -$951K 0.01% 942
2020
Q3 		$32M Buy
852,540
+62,103
+8% +$1.95M 0.01% 1249
2020
Q2 		$25.8M Buy
790,437
+8,455
+1% +$258K 0.01% 1405
2020
Q1 		$22.7M Buy
781,982
+474,058
+154% +$14.7M 0.01% 1309
2019
Q4 		$10.8M Buy
307,924
+9,033
+3% +$250K ﹤0.01% 2126
2019
Q3 		$6.42M Buy
+298,891
New +$8.27M ﹤0.01% 2404

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust's BBIO Position: Q1 2026 in Review

Northern Trust increased its BridgeBio Pharma (BBIO) stake by 4.2% in Q1 2026, buying an estimated $4.12M and bringing the position to 1,403,642 shares worth $104M. The position accounts for 0.01% of the portfolio, ranked #719.

Northern Trust first reported a position in BBIO in Q3 2019 and has held it in 27 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Northern Trust held 1,403,642 shares of BridgeBio Pharma worth $104M as of Q1 2026.
  • Northern Trust bought 56,888 BridgeBio Pharma shares in Q1 2026, an estimated $4.12M.
  • BridgeBio Pharma made up 0.01% of Northern Trust's portfolio in Q1 2026, its #719 holding.
  • Northern Trust first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 27 quarters since.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.